Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.340
+0.040 (3.08%)
At close: Nov 21, 2025, 4:00 PM EST
1.290
-0.050 (-3.73%)
After-hours: Nov 21, 2025, 4:09 PM EST
Zentalis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Zentalis Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $6.17, which forecasts a 360.45% increase in the stock price over the next year. The lowest target is $2.20 and the highest is $10.
Price Target: $6.17 (+360.45%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zentalis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 4 | 4 | 3 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $4 | Hold | Maintains | $8 → $4 | +198.51% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +273.13% | Aug 7, 2025 |
| Wedbush | Wedbush | Hold Reiterates $4 | Hold | Reiterates | $4 | +198.51% | May 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +646.27% | May 15, 2025 |
| Wedbush | Wedbush | Hold Reiterates $4 | Hold | Reiterates | $4 | +198.51% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
n/a
from 67.43M
Revenue Next Year
n/a
EPS This Year
-2.20
from -2.33
EPS Next Year
-2.11
from -2.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.90 | -1.47 | |||
| Avg | -2.20 | -2.11 | |||
| Low | -3.30 | -3.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.